Mark Wildgust

Mark Wildgust is an executive in the oncology division of Johnson & Johnson, a company that collaborated with Legend Biotech to develop CAR-T therapy for multiple myeloma. He played a pivotal role in validating the treatment's effectiveness by personally overseeing investigations into its claims and helping to bring the therapy to patients who had exhausted other options.